Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Specimen Handling 271Magnetic Resonance Spectroscopy 228pembrolizumab 219Carboplatin 180Cisplatin 146Biopsy 143Cyclophosphamide 137Paclitaxel 128Nivolumab 117Gemcitabine 105Bevacizumab 104Radiotherapy 86Dexamethasone 83Pemetrexed 79fludarabine 73Fluorouracil 73Docetaxel 73Doxorubicin 72atezolizumab 71Radiation 71Leucovorin 68Rituximab 65Oxaliplatin 64venetoclax 60Prednisone 59durvalumab 58Cetuximab 56Vincristine 55Etoposide 54Lenalidomide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × JNJ-64264681 × 30 days × Clear all
NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡